Management of limited stage DLBCL without bulky disease
Management of limited stage DLBCL without bulky disease
This algorithm should be used together with related UpToDate topics for diagnosis, staging, management, and follow-up of DLBCL. We consider bulky disease to be a tumor mass ≥10 cm in diameter; PET-negative (Deauville 1-3); and PET-positive (Deauville 4-5).
DLBCL: diffuse large B cell lymphoma; LDH: lactate dehydrogenase; ECOG PS: Eastern Cooperative Oncology Group Performance Status; R-CHOP: rituximab, cyclophsophamide, vincristine, doxorubicin, prednisone; PET3: positron emission tomography after 3 cycles of R-CHOP; ISRT: involved site radiation therapy; Gy: gray; FDG: fluorodeoxyglucose. * Some experts add two additional treatments of rituximab, alone.
